# Generate Biomedicines, Inc. (GENB)

> Source: Nexqual · https://nexqual.com/GENB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Generate Biomedicines, Inc. (GENB), nexqual.com/GENB" · informational, not investment advice.

**Price:** USD 13.06 (+4.31% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 12.52 · day 12.43–13.16 · 52w 11–22.67 · market cap $1.68B · NMS

## Key facts
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 27 (range 22–30).
- Total return with dividends: 1Y +3.2% vs S&P 500 +18.1%; 5Y +3.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -0.55, revenue estimate $7.8M.

## Analysts
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 27 (low 22, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-05 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| 2026-09-08 | HC Wainwright & Co. | Reiterated | Buy | $30 |
| 2026-08-28 | HC Wainwright & Co. | Target raised | Buy | $25 → $30 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-02-27) | 5Y (from 2026-02-23) |
|---|---|---|
| Total return | +3.2% | +3.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | — | — |
| Volatility (annualized) | 86.9% | 71.2% |
| Max drawdown | -39.8% (Aug 2026→Oct 2026) | -25.0% (Jun 2026→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/GENB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt